Kessler Topaz Meltzer & Check, LLP Notifies Sarepta Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the class period from June 22, 2023, to June 24, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Sarepta made false or misleading statements and failed to disclose significant safety risks associated with ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS did not adequately detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have materially misled investors regarding the therapy's approval prospects [2]. Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to seek appointment as a lead plaintiff, representing the class in the litigation [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].